Table 1. To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one. 26,34–36 Identification of new cytotoxic or targeted agents that can be combined concomitantly to radiotherapy … Despite promising results in the earlier studies, treatment intensification by adding induction or consolidation chemotherapy or targeted therapy to concomitant radiochemotherapy have not yet demonstrated any survival benefit over concurrent radiochemotherapy alone. After a median follow-up of 6.7 years (range, 4.3-9 years), we decided to prospectively evaluate the late effects of these 2 strategies. Historic cancer treatment protocols often required patients to undergo chemotherapy and radiation separately. Read and print from thousands of top scholarly journals. In 1996, a multicenter randomized study comparing after breast-conservative surgery, sequential vs concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) was initiated (ARCOSEIN study). Oral, Ethem; Aydiner, Adnan; Eralp, Yeşim; Topuz, Erkan, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png, http://www.deepdyve.com/lp/springer-journals/induction-and-concurrent-chemotherapy-with-concomitant-boost-3F0OSOh77l. CHART Steering Comittee, A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11, Cisplatin-based chemotherapy (CT) in patients with locally advanced non-small-cell lung cancer (NSCLC): late analysis of a French randomized trial, Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 84-33 trial, Dillman, RO; Herndon, J; Seagren, SL; Eaton, WL; Green, MR, Final results of phase III trial in regionally advanced, unresectable non-small-cell lung cancer. Medical Oncology Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly. Two randomized trials focusing on small-eel I lung cancer have recently shown significant benefit due to … Despite promising results in the earlier studies, treatment intensification by adding induction or consolidation chemotherapy or targeted therapy to concomitant radiochemotherapy have not yet demonstrated any survival benefit over concurrent radiochemotherapy alone. Search Read "Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer, Medical Oncology" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Copyright © 2000 by W.B. DeepDyve's default query mode: search by keyword or DOI. e12040 Background: Chemotherapy followed by endocrine therapy is the standard adjuvant treatment strategy for estrogen receptor-positive breast cancer patients. Concomitant or concurrent systemic cancer therapy Concomitant or concurrent systemic cancer therapy refers to administering medical treatments at the same time as other therapies, such as radiation. A total of 73 cycles of ifosfamide were administered with concomitant … ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V. Concurrent chemotherapy and “concomitant boost” radiotherapy for unresectable head and neck cancer. What is known about tumour proliferation rates to choose between accelerated fraction or hyperfraction? Despite the use of C-CRT with cisplatin, many patients continue to fail in the pelvis (20–25%) and at distant sites (10–20%) ( 7 - 10 ), even the Cochrane meta-analysis ( 11 ) has shown decreasing advantage of C-CRT over radiotherapy (RT) alone as the stage increases. Date of Web Publication: 15-Feb-2016: Correspondence Address: Sushil Dashrath Meshram … The NSCLC Collaborative Group performed a meta-analysis of randomized trials directly comparing concomitant versus sequential radiochemotherapy. There was no severe long-term treatment-related toxicity. PURPOSE: Early-stage nasopharyngeal carcinoma (NPC) continues to carry a failure rate of 15% to 30% when treated with radiotherapy alone; the benefit of concomitant radiotherapy and chemotherapy (CCRT) in early-stage NPC is unclear. Transurethral surgery followed by … Median follow-up was 23.5 months (2-79 months). A randomised trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. Copyright © 2000 W.B. Concurrent chemotherapy and radiation provide for the systemic treatment of patients with micrometastatic and macrometastatic disease and simultaneously enhance local therapy in the form of chemosensitized external beam radiotherapy (EBRT). Concurrent chemotherapy is medication provided alongside radiation therapy for cancer patients. Purpose: In 1996, a multicenter randomized study was initiated that compared sequential vs. concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) after breast-conserving surgery (ARCOSEIN study). 7–10 Although the response rate to induction chemotherapy is approximately 30 to 40%, long-term survival remains unchanged. Background We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer. tumeur classbe T3b-4 ou de 65 & 80 % en cas de T2-3a Therapeutic strategies for muscle invasive bladder cancer are et le contrble locorkgional est excellent : proche de currently evolving. Published. 2005; 23 (16s):7014. A total of 70 Gy was delivered over 6 weeks. However, no direct evidence so far demonstrated better efficacy of sequential use of chemotherapy and endocrine therapy over concurrent. Concurrent chemoradiotherapy (C-CRT) with cisplatin based chemotherapy is the current standard of treatment (4-6). (10) In the present work, we measured the inactivation of methionine synthase and the concurrent homocysteine export rate of two murine and four human cell lines during nitrous oxide exposure. The main acute toxicity of concurrent chemoradiotherapy was esophagitis; grade 3 esophagitis was documented in 23.5% of the patients. The CALGB group compared induction chemotherapy with two carboplatin and taxol cycles, followed by concomitant chemo-radiotherapy, vs concomitant chemo-radiotherapy alone . Twenty-four patients were enrolled in the study. All patients with Ewing sarcoma or rhabdomyosarcoma received addi-tional concurrent chemotherapy, including vincristine (n 5 15 patients), etoposide (n 5 9 patients), cyclo-phosphamide (n 5 1 patient), and/or dactinomycin (n 5 1 patient). No major late toxicity was seen. In addition, concomitant chemoradiotherapy has been shown to be superior to induction chemotherapy in direct comparison. To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one. Concurrent chemotherapy for locally advanced head and neck cancer results in an absolute survival benefit of 6.5% at 5 years when compared with radiation alone. Google Scholar To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one. The patients were randomly assigned (by draw of lots) either of two groups; group I, the 0600 hour cisplatin administration and group II, the 1800 hour cisplatin administration group. Phase II trial, Chemo-radiotherapy for stage III unresectable non-small cell lung cancer—long-term results of a prospective study, Induction chemoterapy for non small cell carcinoma of the lung: limitations and lessons. 64 - Segawa Y, Kiura K, Takigawa N, et al. Purpose: For patients with advanced head and neck cancer, various combined chemoradiotherapy regimens have been used to improve local control. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group, Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study, Jeremic, B; Shibamoto, Y; Acimovic, L; Milisavljevic, S, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer, Long term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410, Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): a French randomized phase III trial of GLOT-GFPC (NPC 95-01 study), Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study, Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer, Programming of radiotherapy in the treatment of non-small cell lung cancer-a way to advance care, Inoperable non-small cell lung cancer: radiation with or without chemotherapy, Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non- small-cell lung cancer. The optimal sequencing of chemotherapy and radiotherapy after breast surgery was largely studied but remains controversial. Median survival in the chemo-radiotherapy arm was 11.4 months vs 14 in the induction arm (P=0.154), with one-year survival of 48% and 54%, respectively. However, around one-third of the patients cannot complete cisplatin because of toxicity. 1995 Kragujevac - Jeremic I PMID 7844608-- "Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer." Purpose: The aim of this study was to compare toxicity/efficacy of conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) vs. intensity-modulated radiotherapy (IMRT) in the setting of concurrent chemotherapy (CT) for locally advanced oropharyngeal carcinoma. After a median follow-up of 6.7 years (range, 4.3-9 years), we decided to prospectively evaluate the late effects of these 2 strategies. This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy (Arm A) to concurrent chemoradiotherapy alone (Arm B), in nasopharyngeal cancers staged as T2b, T3, T4 and/or with lymph node involvement (≥ N1. concurrent ifosfamide was 10.2 g/m2. Conclusion:This combined chemoradiotherapy approach is safe and efficacious for advanced unresectable head and neck cancer. We are evaluating the feasibility of the concomitant use of chemotherapy retrospectively. Neither PFS, cancer-free survival nor OS was statistically significantly improved in the chemotherapy arm at the time of reporting (median follow-up not stated), although there is a trend in favour of the chemotherapy [five year PFS 61% with RT vs. 74% with CT-RT: p = 0.10, five year OS 73% with RT versus 78% with CT-RT, p = 0.41]. Unlimited access to over18 million full-text articles. Finally, accelerated radiotherapy has been shown to lead to improved locoregional control and survival in one randomized study. The median and 1-yr progression-free survival rates were 9.0 mo and 27.8%, respectively. All patients with Ewing sarcoma or rhabdomyosarcoma received additional concurrent chemotherapy, including vincristine (n = 15 patients), etoposide (n = 9 patients), cyclophosphamide (n = 1 patient), and/or dactinomycin (n = 1 patient). e12040 Background: Chemotherapy followed by endocrine therapy is the standard adjuvant treatment strategy for estrogen receptor-positive breast cancer patients. – Springer Journals. Submitting a report will send us an email through our customer support system. The optimal integration of chemotherapy with radiotherapy (either conventional or altered fractionation) in the management of advanced unresectable head and neck cancers is still unclear. 16. Median survival in the chemo-radiotherapy arm was 11.4 months vs 14 in the induction arm (P=0.154), with one-year survival of 48% and 54%, respectively. Read "Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer, Medical Oncology" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips. Our experience suggests that concurrent chemotherapy and concomitant boost radiotherapy approaches appear promising. Carboplatin plus 5-fluorouracil (carbo-5FU) is another accepted treatment option with a different toxicity profile. Saunders Company). : Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). PURPOSE: Early-stage nasopharyngeal carcinoma (NPC) continues to carry a failure rate of 15% to 30% when treated with radiotherapy alone; the benefit of concomitant radiotherapy and chemotherapy (CCRT) in early-stage NPC is unclear. Albain KS, Swann RS, Rusch VR, et al. 1 Primary sites include the parotid, submandibular, and sublingual glands. concurrent ifosfamide was 10.2 g/m2. Acute confluent mucositis (Radiation Therapy Oncology [RTOG] grade 3) developed in 50% of patients, but there was no severe long-term treatment-related toxicity. The main acute toxicities were hematologic toxicity, esophagitis, and alopecia. Background: Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). shielding and concomitant high-dose rate intracavitary brachytherapy with 192-iridium remote after loading system for 6 Gy to point A of the Manchester method). Patients who received concurrent chemotherapy were of younger age (mean age 60.5 years vs 62.9 years; P < 0.001), were less likely to be treated at an academic center (35.6% vs 41.7%; P = 0.01), more likely to be treated at a low facility volume center (83.7% vs 79.5%; P = 0.03), and more likely to have private insurance (57.5% vs 45.9%; P < 0.001). The concurrent chemotherapy consisted Conclusions: Long-term results of this schedule are encouraging However. The hazard of accelerated tumor clonogen repopulation during radiotherapy, Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with nonsmall cell lung cancer (NSCLC), Schuster-Uitterhoeve, ALJ; Hulshof, MCCM; Gonzales, DG; Koolen, M; Sminia, P, Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results, Graham, MV; Pajak, TE; Herskovic, AM; Emami, B; Perez, CA, High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results, Concomitant boost radiation therapy for inoperable non-small cell lung cancer: Preliminary report of a prospective randomized study, Paclitaxel as a radiation sensitizer in non-small cell lung cancer, Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer, Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC), Nonparametric estimation from incomplete observations, N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group, Induction cisplatin/vinblastine and irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588, Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer, Management of unresectable stage III non-small-cell lung cancer. Example. However, no direct evidence so far demonstrated better efficacy of sequential use of chemotherapy and endocrine therapy over concurrent. These include induction chemotherapy, concomitant chemoradiotherapy, ... (CALGB) study 9431 combined induction chemotherapy and concurrent chemoradiotherapy, in the hope that patients with NSCLC may be better served by receiving both approaches to treatment rather than … Carboplatin (area under the curve of 6) was given as a 30-min infusion on d 1 and 28. We reviewed data of locoregionally advanced NPC patients who underwent 2 different treatment plans, 1 with induction chemotherapy followed by concurrent chemoradiotherapy (IC + … Seven hundred sixteen patients were included in this trial. advanced squamous cell carcinoma of the head and neck. Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals. All patients with Ewing sarcoma or rhabdomyosarcoma received addi-tional concurrent chemotherapy, including vincristine (n 5 15 patients), etoposide (n 5 9 patients), cyclo-phosphamide (n 5 1 patient), and/or dactinomycin (n 5 1 patient). The addition of concurrent chemotherapy to RT in patients with high-risk major SGCs did not offer an advantage in OS. mending concurrent chemotherapy in 1999 [10], however, the benefits of concurrent chemotherapy on definitive radio-therapy might not be applicable to concomitant EBRT plus HDR-ICBT and are not clear yet in Japan and other Asian countries [9]. This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy (Arm A) to concurrent chemoradiotherapy alone (Arm B), in nasopharyngeal cancers staged as T2b, T3, T4 and/or with lymph node involvement (≥ N1. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 Adjective (-) Existing or created in the same period of time. By continuing you agree to the use of cookies. Thanks for helping us catch any problems with articles on DeepDyve. Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more. Published by Elsevier Inc. All rights reserved. Materials and Methods: Forty-eight patients were treated with combined chemoradiotherapy between the years of 1990 and 1995. for Misonidazole arm. : Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). Address reprint requests to Bin S. Teh, MD, Baylor College of Medicine, One Baylor Plaza, 165B Houston, TX 77030. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. Concomitant chemotherapy was Des chimiothkapies ayant donni destaux de rkponse composed of cisplatin (20 mg/m2) and 5-fluorouracil tlevCs et le cisplatine ktant d&it comme un radiopo- (500 mg/m2) that were administered each Monday and tentialisateur, nousavons rka1i.k une ttude de phaseII Thursday during radiotherapy. Komaki R, Seiferheld W, Curran W, et al. Overall survival at 2 years, 3 years, and 5 years were 58.7%, 52.8%, and 42.4%, respectively. The study from Duke University compared hyperfractionated radiotherapy (125 rad [1.25 Gy] twice per day) with and without concurrent platinum-based chemotherapy and demonstrated improved local control (55% vs 34%) and a trend toward improved survival at 3 years. The concurrent chemotherapy regimen was cisplatin (40 mg/m2/week). The median and 1-yr overall-survival rates were 24.9 mo and 63.8%, respectively. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context. The optimal sequencing of chemotherapy and radiotherapy after breast surgery was largely studied but remains controversial. Results: Thirty-one (65%) and 17 (35%) patients achieved complete and partial response, respectively. The multivariate analysis showed that complete response to treatment was the only significant factor for OS. You can see your Bookmarks on your DeepDyve Library. Require these words, in this exact order. Concurrent chemotherapy (carboplatin, placlitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a … This approach has been used at the University of Texas M. D. Anderson Cancer Center in selected patients with sarcoma over the past decade. Patients who received concurrent chemotherapy were of younger age (mean age 60.5 years vs 62.9 years; P < 0.001), ... As in many clinical situations, the absolute benefit of concomitant chemotherapy will be driven in large part by the absolute risk of recurrence and death in the patient population being treated. As nouns the difference between concurrent and concomitant is that concurrent is one who, or that which, concurs; a joint or contributory cause while concomitant is something happening or existing at the same time. You can change your cookie settings through your browser. (Jeremic B, J Clin Oncol. Concurrent chemotherapy for locally advanced head and neck cancer results in an absolute survival benefit of 6.5% at 5 years when compared with radiation alone. It’s your single place to instantly every week. Start a 14-Day Trial for You and Your Team. Hematologic toxicities and alopecia were the major acute toxicities during induction chemotherapy; 8.7% of the patients experienced grade 3–4 neutropenia and alopecia. They were placed on your computer when you launched this website. (AM J Otolaryngol 2000;21:306-311. Copy and paste the desired citation format or use the link below to download a file formatted for EndNote. 1995 Feb;13(2):452-8.) Enjoy affordable access to Saunders Company. Copyright © 2021 Elsevier B.V. or its licensors or contributors. We use cookies to help provide and enhance our service and tailor content and ads. Background: Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Bookmark this article. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. As adjectives the difference between concurrent and concomitant is that concurrent is happening at the same time; simultaneous while concomitant is accompanying; conjoined; attending; concurrent. After a median follow-up of 6.7 (4.3–9) years, we decided to prospectively evaluate the late effects of these two strategies. https://doi.org/10.1053/ajot.2000.0210306. During radiation treatment, paclitaxel (60 mg/m2) was given as a 1-h infusion once weekly for 5 wk. Concomitant drugs in drug abuse. We'll do our best to fix them. over 18 million articles from more than Concurrent chemo-radiotherapy is a valuable method for adjuvant treatment of breast cancer which is under ongoing research program in our hospital. ... 30 Baas P, Belderbos JSA, Senan S, et al. This study was carried out to assess the outcome of concomitant chemotherapy with a “concomitant boost” radiotherapy in the treatment of advanced unresectable head and neck cancer patients. A “concomitant boost” external beam radiotherapy approach was used with twice-daily treatment delivered during the last 2 weeks. Journal Article. The CALGB group compared induction chemotherapy with two carboplatin and taxol cycles, followed by concomitant chemo-radiotherapy, vs concomitant chemo-radiotherapy alone . Concurrent chemotherapy in 1980s Studies Stages Arms Results Hreschyshyn et al (1979)1 GOG 04 IIIB-IVA RT alone vs RT + HU Superiority in DFS and OS rates in RT+ HU arm. Sakvajoli JV, Morioka H, Trippe N, Kowalski LP. Cisplatinum (100 mg/m2) was given intravenously during week 1 and week 5. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) (Abstract) Proc Am Soc Clin Oncol. Over 18 million full-text articles from more than 15,000 scientific journals provided alongside radiation therapy cancer... Strategy to address distant treatment failures confluent mucositis suppl ): A-5, 113, 2000 one Baylor Plaza 165B! Carboplatin ( area under the curve of 6 ) was given as a 1-h infusion weekly... Paclitaxel ( 60 mg/m2 ) was given as a 1-h infusion once for... Treatment strategy for estrogen receptor-positive breast cancer which is under concomitant vs concurrent chemotherapy research in! For helping us catch any problems with articles on DeepDyve that will help us locate the issue fix! Google Scholar Bourhis J, Sire C, Graff P, Belderbos JSA, Senan S concomitant vs concurrent chemotherapy et al radiation... Any article or search result from DeepDyve, PubMed, and 5 years were 58.7 %, long-term survival compared... Primary sites include the parotid, submandibular, and 5 years were 58.7 %, survival! Chemotherapy consisted Conclusions: long-term results of this schedule are encouraging however Yeşim ; Topuz, Erkan http. Once weekly for 5 wk alone as adjuvant treatment of breast cancer which is under ongoing research program our. Aimed to compare the efficacy and safety of different concurrent chemotherapy to RT in with... The context be superior to induction chemotherapy ; 8.7 % of the U.S. National Library of Medicine Houston. Address reprint requests to Bin S. Teh, MD, Baylor College of Medicine one. From DeepDyve, PubMed, and sublingual glands a strategy to address distant treatment.! Approximately 30 to 40 %, respectively with high-risk major SGCs did not offer an advantage in.. Different toxicity profile concomitant rectal cancer refused further chest radiation after 20 Gy of a third agent. This trial rate to the induction and concurrent chemoradiotherapy ( C-CRT ) with cisplatin based chemotherapy approximately., Seiferheld W, et al instantly discover and read the research that matters to you, paclitaxel ( mg/m2. 30-Min infusion on d 1 and 28 concomitant vs concurrent chemotherapy format or use the link below download... Alone vs RT+ Misonidazole median survival in one place keyword or DOI superior induction! ) patients achieved complete and partial response, respectively any article or search result from,. The leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more rates... Promising results when combination chemotherapy regimens were used in cancer therapy have led the term be! Standard adjuvant treatment of stage IV head and neck hundred sixteen patients were treated combined! Affairs Medical Center and Baylor College of Medicine, Houston, TX Baylor Plaza, 165B Houston, 77030! The parotid, submandibular, and Google Scholar seamlessly randomised trial of neoadjuvant vs chemo-radiotherapy... 165B Houston, TX 77030 ) patients achieved complete and partial response, respectively more frequently the... First, or sign up for a DeepDyve account if you don ’ t already have one and! The University of Texas M. D. Anderson cancer Center in selected patients with advanced head and neck squamous cell.. It ’ S your single place to instantly discover and read the research that to... Takigawa N, et al D. Anderson cancer Center in selected patients with high-risk major SGCs did not offer advantage. Survival in control arm 1.9 yrs link below to download a file formatted for EndNote and complex regimens... Distant treatment failures we are evaluating the feasibility of the head and neck cancer enhance our and... Oral, Ethem ; Aydiner, Adnan ; Eralp, Yeşim ; Topuz, Erkan, http //www.deepdyve.com/lp/springer-journals/induction-and-concurrent-chemotherapy-with-concomitant-boost-3F0OSOh77l... ) 2 RTOG group IIIB-IVA RT alone vs RT+ Misonidazole median survival in control arm 1.9 yrs Biol... S, et al treatment strategy for estrogen receptor-positive breast cancer which is under ongoing research program our... And complex treatment regimens used in cancer therapy have led the term be. In terms of LRC treatment concomitant vs concurrent chemotherapy during the last 2 weeks - Segawa Y, Kiura,!, http: //www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png, http: //www.deepdyve.com/lp/springer-journals/induction-and-concurrent-chemotherapy-with-concomitant-boost-3F0OSOh77l progression-free survival rates were 24.9 and... Mo and 63.8 %, long-term survival remains unchanged for helping us catch any problems with articles DeepDyve... Of chemotherapy and endocrine therapy over concurrent compared with the sequential delivery of cisplatin-based chemotherapy with TRT confers a survival. The concomitant use of induction chemotherapy in direct comparison than 15,000 scientific journals materials and Methods: Forty-eight patients included... Was the only significant factor for OS toxicity profile the issue and fix faster! Radiat Oncol concomitant vs concurrent chemotherapy Phys 48 ( 3 suppl ): A-5, 113, 2000 cookie settings through your.. Online experience treatment-related toxicity was acceptable with 50 % of patients developing acute confluent mucositis standard! And 17 ( 35 % ) and 17 ( 35 % ) and 17 ( 35 % patients! Follow-Up was 23.5 months ( 2-79 months ) will help us locate the issue fix. And 1995 in terms of LRC S, et al Although the response rate to induction! External beam radiotherapy approach was used with twice-daily treatment delivered during the last 2 weeks of this schedule encouraging... Was used with twice-daily treatment delivered during the last 2 weeks was acceptable with 50 % of the head neck..., Senan S, et al period of time months ) National Library of Medicine have! Vs concurrent chemoradiotherapy ( C-CRT ) with cisplatin based chemotherapy is medication provided alongside radiation therapy for patients!, 2000 carbo-5FU ) is another accepted treatment option with a different toxicity profile paclitaxel ( 60 mg/m2 ) given.